NHS Innovation Accelerator Fellow: Peter Young


The PneuX is designed to stop ventilator-associated pneumonia (VAP), the leading cause of hospital-acquired mortality in Intensive Care Units affecting up to 20,000 patients each year, with a 30% mortality rate costing the NHS £10k – £20k per episode.

PneuX is a cuffed ventilation tube and an electronic cuff monitoring and inflation device which prevents leakage of bacterial laden oral and stomach contents to the lung – a problem associated with all standard tubes.

NIA PneuX 718Progress made through the NIA

During the NIA, Peter has included a focus on:

  • Engaging a growing community of clinical champions through national leaders and presentations at key conferences
  • Building the economic case: an independent health economic evaluation at New Cross hospital in Birmingham demonstrated a saving of £718 per patient who received treatment with the PneuX
  • Developing financial incentives for avoidance of leakage of bacteria to the lungs, including through the Commissioning for Quality and Innovation (CQUIN) framework.


Peter has had international interest in PneuX and is currently working with Massachusetts General Hospital to implement the device.

Additionally, he has worked with the specialised commissioning team at NHS England (London region) to secure a local CQUIN to incentivise uptake of the Pneux.


“We are hugely impressed with the direct benefits to patient safety, through avoidable harm and improving outcomes. We urge health care providers to ensure the system is adopted as best practice. From a patient’s perspective, this is an opportunity that cannot be ignored.”

Fernandes, Co-Chair East of England Citizen’s Senate

Useful contact

Twitter: @peterjyoung101